In this model, the KRAS G12D activating mutation was associated either to TP53 or LKB1 loss in lung epithelium, to parallel selected human NSCLC cases harboring both oncogene activation (KRAS) and oncosuppressor (TP53 or LKB1) loss. This evidence concerns the gene KRAS and non-small cell lung carcinoma.